This HTML5 document contains 118 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
n12	http://dx.doi.org/10.1016/
schema	http://schema.org/
skos	http://www.w3.org/2004/02/skos/core#
rdfs	http://www.w3.org/2000/01/rdf-schema#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n11	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q38470797

rdf:type

wikibase:Item

schema:description

2012年论文 teaduslik artikkel scientific article published on 24 May 2012 2012年论文 artykuł naukowy naučni članak artikel ilmiah artigo científico article científic 2012年論文 научна статия বৈজ্ঞানিক নিবন্ধ artikull shkencor articol științific article scientific 2012年論文 article scientifique vitenskapelig artikkel наукова стаття, опублікована в травні 2012 научни чланак 2012年论文 bài báo khoa học مقالة علمية نشرت في 24 مايو 2012 2012年论文 מאמר מדעי 2012년 논문 artículo científico 2012 nî lūn-bûn vetenskaplig artikel artigo científico научни чланак 2012年論文 научная статья artikulong pang-agham artículu científicu espublizáu en 2012 tudományos cikk 2012年論文 2012年论文 vedecký článok articolo scientifico мақолаи илмӣ scientific article published on 24 May 2012 scientific article published on 24 May 2012 2012年论文 სამეცნიერო სტატია videnskabelig artikel 2012年の論文 artigo científico บทความทางวิทยาศาสตร์ tieteellinen artikkeli vědecký článek 2012年論文 scienca artikolo wetenschappelijk artikel bilimsel makale wissenschaftlicher Artikel vitskapeleg artikkel επιστημονικό άρθρο

p:P577

wds:Q38470797-78549809-8CAD-42A3-AE0D-035EEAB39DAA

wdt:P577

2012-05-24T00:00:00Z

p:P2093

wds:Q38470797-13B94471-1144-4207-B643-5DE9AF2D2113 wds:Q38470797-1B61B60E-15B3-4D31-8A98-ADDED1663989 wds:Q38470797-07095467-B710-49B6-9E1F-8786F010FCAF wds:Q38470797-09A3CE18-F04B-49CB-AD10-38D486C20C96 wds:Q38470797-85DB3BCD-7C6E-470E-9201-42662E80D5F9 wds:Q38470797-6DEC6D09-89A3-4B83-BB30-2F2614EA2F91 wds:Q38470797-71CC9B9F-1585-4E4B-ACB6-01BD59F1AF8F wds:Q38470797-BC4A4C3C-A1C6-4D49-8293-F61FAC1E3E7C wds:Q38470797-A5BCDBD1-E034-4A52-BB7F-39BFB538F350 wds:Q38470797-953B9740-A72E-4FB3-B2E8-DD075294DCC1 wds:Q38470797-CC5146BA-DCDE-4C7F-AB4F-CCC3F5894E5E wds:Q38470797-D14D56CE-8BEC-49B0-85CA-A38C87AF3ED5

wdt:P2093

Junwa Shen Jennifer Zeinecker Wayne Greaves Marcos M Caseiro Jose L de Andrade Neto Antonio Solano Ricardo S Diaz Jihad Slim Lisa M Dunkle Carmen Mak Mark Nelson Regis A Vilchez

rdfs:label

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials

skos:prefLabel

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials

schema:name

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials

p:P50

wds:Q38470797-8829D8C0-3005-47FD-A76B-FBB1D2880A88 wds:Q38470797-9948EFA5-0A77-4C0E-938A-E3B65F391651

wdt:P50

wd:Q114417887 wd:Q55271295

p:P1476

wds:Q38470797-CBC0F96C-EA85-4365-AF66-9DEC38F47205

wdt:P1476

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials

p:P304

wds:Q38470797-C559E222-A9F8-493A-916F-3E9EE595B76F

wdt:P304

326-335

p:P31

wds:Q38470797-972DAA38-4A5D-4CE9-A51F-B174950357C5

wdt:P31

wd:Q13442814

p:P921

wds:Q38470797-C1AECF32-2C2E-4A60-B315-D87C46F8BEE3

wdt:P921

wd:Q42824827

p:P698

wds:Q38470797-733554CA-1F0E-4B39-876B-C45588C1D097

wdtn:P698

n11:22634184

wdt:P698

22634184

p:P1433

wds:Q38470797-4B7EA134-5D1B-405C-9475-A8FFEBB36917

wdt:P1433

wd:Q6295344

p:P433

wds:Q38470797-CB0D4C30-2E2A-4543-8A49-729480F9C776

p:P478

wds:Q38470797-5AAD3CB6-D3C0-4D1C-AA87-A6B7401F9B3C

wdt:P433

4

wdt:P478

65

p:P356

wds:Q38470797-C04FBF60-4508-4E22-A442-33DD830F2D19

wdtn:P356

n12:J.JINF.2012.05.008

wdt:P356

10.1016/J.JINF.2012.05.008